SaMD Localization Services

SaMD companies typically need localization services covering UI strings, microcopy, onboarding flows, notifications, alerts, clinical workflow text, patient-facing instructions, consent text, IFUs, eIFUs, release notes, support articles, app-store content, regulatory documentation, risk management content, usability documentation, training materials and websites. Localization is needed across many languages depending on target markets and across many software releases. The objective is accurate, complete and source-faithful localization aligned to the approved source, supported by qualified linguists, controlled medical and software terminology, in-context review and traceable workflows proportionate to content risk.

Localization inside a SaMD company is typically managed or initiated by Product Managers, Developers, Software Localization Managers, UX Managers, Documentation Managers, Regulatory Affairs Managers and Clinical Affairs Managers. Quality, validation, support and marketing teams also generate localization needs. Responsibility is often spread across departments and release teams, which can create terminology drift, duplicated suppliers and weaker traceability. A consolidated approach with a specialised partner helps centralise multilingual content, align UI and documentation terminology and provide consistent evidence across releases, content types and markets.

Regulated software localization is the multilingual adaptation of software content subject to regulatory expectations, including SaMD, medical device software, healthcare apps and digital therapeutics. It covers UI strings, alerts, clinical workflow text, patient-facing content, IFUs, eIFUs, release notes, support content and regulatory documentation. Regulated software localization focuses on accurate, traceable multilingual content aligned to the approved source, with terminology control, version management and in-context review. It does not replace product, regulatory, medical, UX, software validation, usability validation or quality decisions, which remain with the SaMD company and its qualified internal reviewers.

Medical software localization differs from general software localization services because the content sits within a regulated framework and may affect user actions, clinical workflows, patient understanding, safety information and authority-facing documentation. It requires linguists with healthcare and software expertise, terminology aligned with medical and regulatory references, careful handling of alerts and safety wording, in-context review for UI and stronger traceability through translation certificates. General software localization services focus mainly on functional and UX accuracy, while medical software localization adds clinical precision, regulated documentation discipline and review structures suitable for SaMD environments and notified body or competent authority expectations.

Terminology control is important because SaMD content repeats across UI, microcopy, alerts, onboarding flows, notifications, clinical workflow text, patient instructions, IFUs, eIFUs, release notes, support articles, regulatory documentation and marketing content. Inconsistent terminology across these assets can affect usability, regulatory documentation, audit findings and rework during software validation or release reviews. Validated glossaries, translation memories, style guides and reusable controlled content help SaMD companies keep multilingual content aligned across releases, suppliers and markets, supporting consistency that fits into the quality management system and regulated software documentation expectations.

No. The objective of every workflow is accurate, complete and source-faithful localization. What changes is the workflow used to manage the risk of not achieving that objective, the review depth, the cost and the turnaround. Lower-risk workflows may be appropriate for internal drafts, administrative support text, repeated UI strings, help content or low-impact updates when internal controls support that decision. They are different processes for managing localization risk, not lower accuracy requirements. Higher-risk content such as medical software UI, clinical workflows, patient instructions, alerts, IFUs and regulatory documentation typically follows more robust workflows with independent revision.

No. SaMD localization helps you produce accurate, traceable multilingual content aligned to your approved source, but it does not guarantee regulatory approval, medical device classification, software validation, AI system performance, clinical validation, usability validation, authority acceptance, app-store approval, patient understanding, safe use, market access or business outcomes. Product strategy, software validation, regulatory submissions, clinical decisions, AI governance and final content approval remain with your internal product, development, regulatory, UX, clinical, quality and legal teams. AbroadLink acts as a specialised language partner supporting your processes, not replacing them.

CertLink is AbroadLink's portal for accessing translation certificates linked to your projects. Each certificate is signed and includes the project code, languages, content covered, linguists involved and, where relevant, information about controlled AI use during pre-translation. For SaMD companies, CertLink provides a centralised, searchable place to retrieve evidence of localization work across releases and markets, which can support internal release records, regulatory submissions, audits and authority questions. It complements, but does not replace, your internal product, regulatory, software validation, usability validation, quality and QMS records, which remain under your responsibility.